Key result
TD-0714 was well-tolerated and produced dose-proportional pharmacokinetics with sustained increases in plasma cGMP (~50-100% above baseline) in healthy adult and elderly subjects.
Why the study?
TD-0714 is an orally active, potent, and selective neprilysin inhibitor in development for the treatment of chronic heart failure.
Does TD-0714 demonstrate safety, predictable pharmacokinetics, and target engagement (increased cGMP) in healthy adult and elderly subjects?
RCT
Double-blind
Randomized
Does TD-0714 demonstrate safety, predictable pharmacokinetics, and target engagement (increased cGMP) in healthy adult and elderly subjects?
TD-0714, a novel neprilysin inhibitor, demonstrates a favorable safety profile and sustained target engagement in healthy volunteers, supporting its further development for heart failure.
Supports progression to patient studies; extends safety and PD data to elderly volunteers.
TD-0714 is an orally active, potent, and selective inhibitor of human neprilysin (NEP) in development for the treatment of chronic heart failure. Oral administration of TD-0714 in rats resulted in dose-dependent and sustained increases in plasma cyclic guanosine monophosphate (cGMP) over 24 hours consistent with NEP target engagement. Randomized, double-blind, placebo controlled, single ascending dose (50-600 mg TD-0714) and multiple ascending dose (10-200 mg TD-0714 q.d. for 14 days) studies were conducted in healthy volunteers. TD-0714 was generally well-tolerated and no serious adverse events or clinically significant effects on vital signs or electrocardiogram parameters were observed. TD-0714 exhibited dose-proportional pharmacokinetics (PKs) with high oral bioavailability, minimal accumulation after once daily dosing, and negligible renal elimination. Pharmacodynamic (PD) responses were observed at all dose levels studied, as reflected by statistically significant increases in plasma cGMP concentrations. The increases in cGMP were significantly above the baseline (~ 50-100%) on day 14 for the entire 24-hour interval indicating that sustained cGMP elevations are achieved at steady-state. Maximal steady-state cGMP response was observed in plasma and urine at doses ≥ 50 mg. The TD-0714 PK-PD relationship and safety profile were similar in elderly vs. younger adult subjects. The TD-0714 PK and PD profiles support further clinical development of TD-0714 and suggest the potential for once-daily administration and predictable exposure in patients with cardiorenal diseases regardless of their renal function.
No takes yet. Share an insight, caveat, or question.
Kanodia et al. (2020) conducted an RCT in Healthy volunteers. TD-0714 vs. Placebo was evaluated on Safety, pharmacokinetics, and pharmacodynamics (plasma cGMP concentrations). TD-0714 was well-tolerated and produced dose-proportional pharmacokinetics with sustained increases in plasma cGMP (~50-100% above baseline) in healthy adult and elderly subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: